Our data suggest that although most intramuscularly injected COVID-19 vaccines induced minimal anti-spike IgA responses, breakthrough infection via the mucosal route synergistically improved both systemic and mucosal anti-viral immunity, but the mucosal IgA response appeared to wane within 20 weeks. Here, CD79A is linked to infection.